Marion, Alcantara
Marion, Chevrier
Fabrice, Jardin
Anna, Schmitt
Caroline, Houillier
Lucie, Oberic
Olivier, Chinot
Franck, Morschhauser
Frédéric, Peyrade
Roch, Houot
Khê, Hoang-Xuan
Hervé, Ghesquieres
Carole, Soussain
Article History
Received: 31 July 2024
Accepted: 6 September 2024
First Online: 19 September 2024
Declarations
:
: The study was conducted in compliance with Good Clinical Practice, as defined by the International Conference on Harmonization and according to applicable regulatory requirements. The study protocol and all amendments were approved by the competent authority and independent ethics committee. All patients, or the persons on confidence in case the neurological status of the patient did not allow him to understand and/or to sign, provided written informed consent before enrollment.
: Not applicable.
: AM performed scientific and medical consulting for Novartis, Janssen, Kite/Gilead and MSD and received research grants from Mnemo Therapeutics. OL has received honoraria and travel fundings from Roche, Kite/Gilead, BMS, Janssen and AstraZeneca. HR has received honoraria from Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche; and is a member on an entity’s Board of Directors or advisory committees of Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, ADC Therapeutics, Incyte and Miltenyi. SC received a research grant from AstraZeneca.